Your browser doesn't support javascript.
loading
Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy.
Patterson, Claire M; Balachander, Srividya B; Grant, Iain; Pop-Damkov, Petar; Kelly, Brian; McCoull, William; Parker, Jeremy; Giannis, Michael; Hill, Kathryn J; Gibbons, Francis D; Hennessy, Edward J; Kemmitt, Paul; Harmer, Alexander R; Gales, Sonya; Purbrick, Stuart; Redmond, Sean; Skinner, Matthew; Graham, Lorraine; Secrist, J Paul; Schuller, Alwin G; Wen, Shenghua; Adam, Ammar; Reimer, Corinne; Cidado, Justin; Wild, Martin; Gangl, Eric; Fawell, Stephen E; Saeh, Jamal; Davies, Barry R; Owen, David J; Ashford, Marianne B.
Afiliación
  • Patterson CM; Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield, SK10 2NA, UK.
  • Balachander SB; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA.
  • Grant I; Pharmaceutical Technology and Development, Operations, AstraZeneca, Macclesfield, SK10 2NA, UK.
  • Pop-Damkov P; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA.
  • Kelly B; Starpharma, 4-6 Southampton Crescent, Abbotsford, VIC, 3067, Australia.
  • McCoull W; Oncology R&D, AstraZeneca, Cambridge, CB4 0FZ, UK.
  • Parker J; Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield, SK10 2NA, UK.
  • Giannis M; Starpharma, 4-6 Southampton Crescent, Abbotsford, VIC, 3067, Australia.
  • Hill KJ; Pharmaceutical Technology and Development, Operations, AstraZeneca, Macclesfield, SK10 2NA, UK.
  • Gibbons FD; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA.
  • Hennessy EJ; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA.
  • Kemmitt P; Oncology R&D, AstraZeneca, Cambridge, CB4 0FZ, UK.
  • Harmer AR; Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, CB4 0FZ, UK.
  • Gales S; Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, CB4 0FZ, UK.
  • Purbrick S; Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, CB4 0FZ, UK.
  • Redmond S; Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Boston, MA, 02451, USA.
  • Skinner M; Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, CB4 0FZ, UK.
  • Graham L; Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield, SK10 2NA, UK.
  • Secrist JP; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA.
  • Schuller AG; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA.
  • Wen S; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA.
  • Adam A; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA.
  • Reimer C; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA.
  • Cidado J; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA.
  • Wild M; Oncology R&D, AstraZeneca, Cambridge, CB4 0FZ, UK.
  • Gangl E; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA.
  • Fawell SE; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA.
  • Saeh J; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA.
  • Davies BR; Oncology R&D, AstraZeneca, Cambridge, CB4 0FZ, UK.
  • Owen DJ; Starpharma, 4-6 Southampton Crescent, Abbotsford, VIC, 3067, Australia.
  • Ashford MB; Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield, SK10 2NA, UK. Marianne.Ashford@astrazeneca.com.
Commun Biol ; 4(1): 112, 2021 01 25.
Article en En | MEDLINE | ID: mdl-33495510
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Dendrímeros / Neoplasias / Antineoplásicos Límite: Animals / Female / Humans / Male Idioma: En Revista: Commun Biol Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Dendrímeros / Neoplasias / Antineoplásicos Límite: Animals / Female / Humans / Male Idioma: En Revista: Commun Biol Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido